



**Certificate of Mailing 37 C.F.R. §1.8(a)**

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Name of Person Signing Certificate: Renee Conti  
Date: January 14, 2005 Signature: Renee Conti  
Signature

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

First Named Inventor:	Cristina Blanco	§
	Fernandez, et al	§
		§
Conf. No.:	8298	§ Group Art Unit: 1621
		§
Appln. No.:	10/799,909	§ Examiner: Peter G. O'Sullivan
		§
Filing Date:	March 12, 2004	§ Attorney Docket No.: 9256-23US § (003/PCT/05-V)
Title:	PROCESS FOR THE SEPARATION OF R(-)- AND S(+)-5-[2-[[2-(2-ETHOXYPHOXY)ETHYL]AMINO]PROPYL]-2-METHOXYBENZENESULFONAMIDE	

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)**

Enclosed are copies of each of the documents listed on the attached Information Disclosure Citation Form(s) PTO/SB/08A, which may be material to the patentability of this application and/or for which there may be a duty to disclose in accordance with 37 C.F.R. §1.56.

The enclosed references were cited in an International Search Report dated February 5, 2004 (copy enclosed) from the Spanish Patent and Trademark Office concerning counterpart International Application No. PCT/ES 03/00357.

The filing of this Information Disclosure Statement shall not be construed as an admission that any of the listed documents constitutes prior art, nor as an admission against interest in any manner.

No fee is believed to be due in connection with the filing of this Information Disclosure Statement since it is being filed before the mailing date of the first Office Action on the merits. However, the Commissioner is hereby authorized to charge any deficiencies or credit any

overpayments to Deposit Account No. 50-1017.

It is respectfully requested that this Information Disclosure Statement and the documents listed on the attached Form PTO/SB/08A be considered and acknowledged by the Examiner in connection with the above-identified patent application, be made of record therein, and that the listed document(s) be cited in the issued patent.

Respectfully submitted,

Cristina Blanco Fernandez, et al


January 14, 2005  
(Date)



William W. Schwarze  
Attorney/Agent for Applicant(s)  
Registration No. 25,918  
Direct Dial: 215-965-1270  
E-Mail: wschwarze@akingump.com

Akin Gump Strauss Hauer & Feld LLP  
One Commerce Square  
2005 Market Street, Suite 2200  
Philadelphia, PA 19103  
Telephone No.: 215-965-1200  
Fax No.: 215-965-1210

WWS:rc  
Enclosures



Form PTO/SB/08A <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>	
<b>Application Number</b>		10/799,909			
<b>Filing Date</b>		March 12, 2004			
<b>First Named Inventor</b>		Cristina Blanco Fernandez, et al			
<b>Group Art Unit</b>		1621			
<b>Examiner Name</b>		Peter G. O'Sullivan			
<b>Sheet</b>	1	<b>of</b>	1	<b>Attorney Docket Number</b>	

FOREIGN PATENT DOCUMENTS					
Exr Initials	Foreign Patent Document			Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY
	Country Code	Number	Kind Code (if known)		
	ES	2 000 382		Yamanouchi Pharmaceutical Co., Ltd.	02-1988
	ES	2 029 838		Yamanouchi Pharmaceutical Co., Ltd.	10-1992
	WO	03/037856	A1	Roche Vitamins AG	05-2003

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T <sub>1</sub>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

T<sub>1</sub> - Place a check mark if complete document is in English; otherwise, place a letter "A" if only an English abstract is attached.